WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Eli Lilly and Company

LillyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

www.lilly.com

Eli Lilly and Company RSS Channel

Filters
List of articles in category Eli Lilly and Company
Title Published Date
Lilly Reports on Outcome of Phase III Study of Arzoxifene 24 August 2009
Effient(TM) is Now Available in Pharmacies 06 August 2009
Top 10 Tips for Staying Healthy When Money is Tight 07 July 2009
Eli Lilly and Company Announces New Drug Discovery Initiative 16 June 2009
Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 20 May 2009
Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene 27 April 2009
Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee 11 February 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices 15 January 2009
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next
  • End

Business & Industry

  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe
  • Pfizer and BioNTech advance COVID-19 vaccine strategy with study start of next-generation vaccine candidate based on enhanced spike protein design

Research & Development

  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19
  • Scientists develop new biomimetic formulation for treating glioblastoma
  • SARS-CoV-2 hijacks nanotubes between neurons to infect them

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Eli Lilly and Company
  4. Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.